Loading...
•
Mar 31, 2023
Alector Q1 2023 Earnings Report
Alector reported its financial results for Q1 2023 and provided a business update.
Key Takeaways
Alector reported a net loss of $45.9 million, or $0.55 per share, for the quarter ended March 31, 2023. As of March 31, 2023, cash, cash equivalents, and investments were $669.3 million. The company expects this to be sufficient to fund operations through 2025.
On track to engage with regulatory authorities on the pivotal Phase 3 INFRONT-3 clinical trial of latozinemab in mid-2023; targeting data readout in early 2025
Plan to present additional results from the entire FTD-C9orf72 cohort in the INFRONT-2 Phase 2 clinical trial of latozinemab during the second half of 2023
Anticipate completing enrollment in the INVOKE-2 Phase 2 clinical trial of AL002 in patients with early Alzheimer’s disease in Q3 2023, with data readout expected by Q4 2024
$669.3 million in cash, cash equivalents and investments provide runway through 2025
Revenue by Segment
Forward Guidance
Management anticipates, for the year ending 2023, collaboration revenue to be between $15 million and $25 million, total research and development expenses to be between $225 million and $245 million and total general and administrative expenses to be between $60 million and $70 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...